GUT MYCOBIOME IN THE SPECTRUM OF METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): FROM MASH TO HEPATOCELLULAR CARCINOMA

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Annals of hepatology Pub Date : 2025-09-01 DOI:10.1016/j.aohep.2025.102044

Cassio Marques Perlin , Melina Keingeski Belén , Bruno de Souza Basso , Beatriz Mendes Borba , Julliane Dutra Medeiros , Francis Moreira Borges , Bernd Schnabl , Mario Reis Alvares-da-Silva

{"title":"GUT MYCOBIOME IN THE SPECTRUM OF METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): FROM MASH TO HEPATOCELLULAR CARCINOMA","authors":"Cassio Marques Perlin , Melina Keingeski Belén , Bruno de Souza Basso , Beatriz Mendes Borba , Julliane Dutra Medeiros , Francis Moreira Borges , Bernd Schnabl , Mario Reis Alvares-da-Silva","doi":"10.1016/j.aohep.2025.102044","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Gut microbiome (GM) dysbiosis is associated with the development and progression of metabolic-dysfunction associated steatotic liver disease (MASLD) and steatohepatitis (MASH). There is still very limited data on the gut mycobiome (GMyco). This study aims to evaluate the composition of the GMyco at different stages of MASLD.</div></div><div><h3>Patients and Methods</h3><div>28 patients were included: controls (CON), n=6; MASH, n=6; cirrhosis (CIR), n=7; and hepatocellular carcinoma (HCC), n=5. Stool samples were collected and stored in a -80°C freezer for DNA extraction and sequencing (18S region). The single sequence variants (ASVs) obtained were compared to the SILVA database.</div></div><div><h3>Results</h3><div>77.93% women, average BMI of 31.4 kg/m2, use of antibiotics in the last 6 months (30.4%), and concurrent lipid-lowering drugs in 26.1%. MASH patients had a greater alpha-diversity (p<0,05) than CON. CON had a higher abundance of Ascomycota phylum, and MASH higher Basidiomycota. CON had higher Aspergillaceae family, while there was a higher abundance of Malasseziaceae and Sporidiobolaceae in CIR and Saccharomycetacea in HCC. Only one ASV (genus Naganishia, previously reported as Cryptococcus) was homogeneously distributed in MASLD and absent in CON.</div></div><div><h3>Conclusions</h3><div>This study shows in an unprecedented way GMyco profile in the different strata of MASLD. Basidiomycetes, higher in MASH, were previously described in obese patients. For the first time, the genus Naganishia was described in this population. Our findings suggest that fungi could be a potential biological marker in the MASLD spectrum in the future.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 102044"},"PeriodicalIF":4.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268125002698","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and Objectives

Gut microbiome (GM) dysbiosis is associated with the development and progression of metabolic-dysfunction associated steatotic liver disease (MASLD) and steatohepatitis (MASH). There is still very limited data on the gut mycobiome (GMyco). This study aims to evaluate the composition of the GMyco at different stages of MASLD.

Patients and Methods

28 patients were included: controls (CON), n=6; MASH, n=6; cirrhosis (CIR), n=7; and hepatocellular carcinoma (HCC), n=5. Stool samples were collected and stored in a -80°C freezer for DNA extraction and sequencing (18S region). The single sequence variants (ASVs) obtained were compared to the SILVA database.

Results

77.93% women, average BMI of 31.4 kg/m2, use of antibiotics in the last 6 months (30.4%), and concurrent lipid-lowering drugs in 26.1%. MASH patients had a greater alpha-diversity (p<0,05) than CON. CON had a higher abundance of Ascomycota phylum, and MASH higher Basidiomycota. CON had higher Aspergillaceae family, while there was a higher abundance of Malasseziaceae and Sporidiobolaceae in CIR and Saccharomycetacea in HCC. Only one ASV (genus Naganishia, previously reported as Cryptococcus) was homogeneously distributed in MASLD and absent in CON.

Conclusions

This study shows in an unprecedented way GMyco profile in the different strata of MASLD. Basidiomycetes, higher in MASH, were previously described in obese patients. For the first time, the genus Naganishia was described in this population. Our findings suggest that fungi could be a potential biological marker in the MASLD spectrum in the future.

查看原文本刊更多论文

代谢功能障碍相关脂肪变性肝病（masld）谱中的肠道菌群：从土豆泥到肝细胞癌

肠道微生物群（GM）失调与代谢功能障碍相关的脂肪性肝病（MASLD）和脂肪性肝炎（MASH）的发生和进展有关。关于肠道菌群（GMyco）的数据仍然非常有限。本研究旨在评价MASLD不同阶段GMyco的组成。患者与方法28例患者：对照组（CON）， n=6；土豆泥,n = 6;肝硬化（CIR）， n=7；肝细胞癌（HCC）， n=5。收集粪便样本，保存在-80°C冷冻箱内，用于DNA提取和测序（18S区）。结果77.93%的女性，平均BMI为31.4 kg/m2，最近6个月内使用抗生素（30.4%），同时使用降脂药物（26.1%）。MASH患者的α -多样性高于CON患者（p < 0.05）， CON患者的子囊菌门丰度更高，而MASH患者的担子菌门丰度更高。CON中曲霉科含量较高，CIR中Malasseziaceae和Sporidiobolaceae含量较高，HCC中Saccharomycetacea含量较高。只有一种ASV （Naganishia属，以前报道为隐球菌）在MASLD中均匀分布，而在con中未发现。结论本研究以前所未有的方式显示了GMyco在MASLD不同地层中的分布。担子菌，在MASH中较高，以前在肥胖患者中被描述过。在该居群中首次发现长岛属。我们的研究结果表明，真菌可能是未来MASLD谱中潜在的生物标记物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of hepatology 医学-胃肠肝病学

CiteScore

7.90

自引率

2.60%

发文量

183

审稿时长

4-8 weeks

期刊介绍： Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.